VENTURE CAPITAL

We use an integrative research process that drives success by unifying naturally divergent perspectives, capabilities, skill sets, and relationships. The process integrates 1) dynamic investment research on thousands of publicly traded and privately held companies with 2) thousands of relationships among executives, investors, and other key participants in our focus areas.

Technology / SaaS
Healthcare
Environmental Technology
SELECT PORTFOLIO COMPANIES
First Analysis is a leading venture capital investor focused on business-to-business technology companies. We have one of the longest records in venture capital, having invested more than $825 million across multiple highly diversified funds over four decades. First Analysis invests mainly in North America with a focus on our sectors of expertise.
We help established companies become profitable leaders in large markets, funding growth plans and working closely with management in areas including strategy, recruitment, sales and marketing, and corporate development. Our flexible approach targets investing $3-10 million as lead investor or as a syndicate partner bringing valuable perspective.

Submit a business plan

Click here to e-mail a business plan.

First Analysis generally invests to expand and grow companies with proven business models and demonstrable customer successes. If you believe an investment in your company is suitable given these general criteria, we would like to learn more about your opportunity. With the information you provide, we can quickly route your information to a First Analysis venture professional who specializes in your industry and who will review and respond to your inquiry.

VENTURE CAPITAL NEWS
First Analysis invests in Applied StemCell, a leading cell and gene therapy CRO/CDMO
First Analysis, a leading venture capital investor, has made a new investment in Applied StemCell (ASC), a contract development and manufacturing organization (CDMO) specializing in tailored cell and gene therapy solutions. First Analysis co-invested in ASC alongside QHP Capital.
July 16, 2024
First Analysis, a leading venture capital investor, has made a new investment in Applied StemCell (ASC), a contract development and manufacturing organization (CDMO) specializing in tailored cell and gene therapy solutions. First Analysis co-invested in ASC alongside QHP Capital.
July 16, 2024
First Analysis invests in Sware, provider of FDA-mandated computer system validation automation for GxP systems and release testing
First Analysis, a leading venture capital investor, has made a new investment in Sware, which provides a complete software validation solution for innovative life sciences companies. The investment will be used to bolster research and development of Sware's computer systems validation (CSV) platform, Res_Q, to further streamline processes with artificial intelligence (AI), and to expand the company's sales team so it can bring the platform to more organizations struggling with validation debt.
June 07, 2024
First Analysis, a leading venture capital investor, has made a new investment in Sware, which provides a complete software validation solution for innovative life sciences companies. The investment will be used to bolster research and development of Sware's computer systems validation (CSV) platform, Res_Q, to further streamline processes with artificial intelligence (AI), and to expand the company's sales team so it can bring the platform to more organizations struggling with validation debt.
June 07, 2024
First Analysis invests in Dina, provider of home-centered care coordination solutions
First Analysis, a leading venture capital investor, has made a new investment in Dina, provider of digital network management and coordination solutions for the Medicare Advantage and managed Medicaid markets, with a particular focus on coordinating supplemental benefits and long-term services and supports (LTSS). The investment will support Dina’s go-to-market strategy as well as continued execution of the product roadmap. First Analysis led the $7 million Series B round.
February 13, 2024
First Analysis, a leading venture capital investor, has made a new investment in Dina, provider of digital network management and coordination solutions for the Medicare Advantage and managed Medicaid markets, with a particular focus on coordinating supplemental benefits and long-term services and supports (LTSS). The investment will support Dina’s go-to-market strategy as well as continued execution of the product roadmap. First Analysis led the $7 million Series B round.
February 13, 2024
©2024 by First Analysis Corporation.
One South Wacker Drive
  ·  
Suite 3900
  ·  
Chicago, IL 60606
  ·  
312-258-1400